Wikipedia

Mahvash disease

Mahvash disease is an autosomal recessive, hereditary pancreatic neuroendocrine tumor syndrome.[1][2] The genetic defect that causes Mahvash disease is biallelic inactivating mutations of the glucagon receptor gene (GCGR).[3] Mahvash disease was discovered by American physician Run Yu and his colleagues in 2008.[4] Mahvash disease is very rare. There have been approximately 15 cases of Mahvash disease described in detail by the end of 2023.[3][4][5][6][7][8][9][10][11] Mahvash disease occurs in both females and males. Mahvash disease is also called “glucagon cell hyperplasia and neoplasia” or “glucagon cell adenomatosis” by some authors but Mahvash disease is a distinct disease entity while the two alternative terms are mostly histological descriptions.[12] Some patients with “glucagon cell hyperplasia and neoplasia” do not have glucagon receptor mutations.

Mahvash disease
Other namesGlucagon cell hyperplasia and neoplasia
Photographic image of the numerous islets of various sizes in the pancreas of a patient with Mahvash disease

Signs and symptoms

edit

Most patients with Mahvash disease are diagnosed in adulthood. Patients with Mahvash disease usually present with vague abdominal discomfort. Imaging with CT or MRI identifies a very large pancreas with one or more tumors. Biochemical testing shows marked hyperglucagonemia (hundreds-fold elevated). If the tumors are resected, they are found to be neuroendocrine tumors that usually express glucagon. In the tumor margin, pancreatic alpha cell hyperplasia is pervasive, numerous large islets composed of mostly alpha cells are evident, and multiple microadenomas and small neuroendocrine tumors often are present. The pancreatic neuroendocrine tumors are the main health concern for patients with Mahvash disease. Although the tumors commonly are indolent, death due to liver metastasis has been reported.[3] In patients with complete loss of glucagon receptor function, Mahvash disease can present at younger age with portal hypertension and hepatic encephalopathy.[11]

Pathogenesis

edit

Mahvash disease is a form of reactive pancreatic alpha cell hyperplasia.[12] The loss of normal glucagon signaling (particularly in the liver) due to inactive glucagon receptor results in enzymatic changes in the liver so that the liver releases abnormally large quantities of amino acids into the circulation.[13] High concentration of amino acids in the circulation (hyperaminoacidemia) stimulates the pancreatic alpha cells (the cells that normally produce glucagon) to proliferate and to produce and release much more glucagon. The enormous proliferative activity of the pancreatic alpha cells predisposes them to tumor formation.[14] All patients with Mahvash disease have hyperaminoacidemia, hyperglucagonemia (high concentration of glucagon in the circulation), and pancreatic alpha cell hyperplasia, and develop pancreatic neuroendocrine tumors in adulthood.[3] The pathogenesis of portal hypertension and hepatic encephalopathy is not clear yet.[11]

Diagnosis

edit

A large pancreas with marked hyperglucagonemia in an adult makes the diagnosis of Mahvash disease very likely. The existence of pancreatic tumors makes the diagnosis even more likely. Histologically, pancreatic alpha cell hyperplasia and microadenomas suggest the diagnosis of Mahvash disease. The final diagnosis of Mahvash disease requires mutational analysis of the glucagon receptor gene.[3]

Treatment

edit

The treatment of Mahvash disease currently focuses on managing the pancreatic neuroendocrine tumors. Small tumors can be monitored but large ones need to be resected. As patients with Mahvash disease have life-long risk of developing pancreatic neuroendocrine tumors, they need to undergo periodic biochemical testing and imaging.[3] Liver transplant is a safe and effective treatment for patients with portal hypertension and hepatic encephalopathy.[11]

References

edit
  1. ^ "Mahvash disease, Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. National Institutes of Health. Retrieved 2018-12-08.
  2. ^ "MAHVASH DISEASE; MVAH, Online Mendelian Inheritance in Man (OMIM)". www.omim.org. Johns Hopkins University. Retrieved 2023-11-23.
  3. ^ a b c d e f Yu R (2018). "Mahvash Disease: 10 Years After Discovery". Pancreas. 47 (5): 511–515. doi:10.1097/MPA.0000000000001044. PMID 29702528. S2CID 13871451.
  4. ^ a b Zhou C, Dhall D, Nissen NN, Chen CR, Yu R (November 2009). "Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor". Pancreas. 38 (8): 941–6. doi:10.1097/MPA.0b013e3181b2bb03. PMC 2767399. PMID 19657311.
  5. ^ Sipos B, Sperveslage J, Anlauf M, Hoffmeister M, Henopp T, Buch S, Hampe J, Weber A, Hammel P, Couvelard A, Höbling W, Lieb W, Boehm BO, Klöppel G (May 2015). "Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations". The Journal of Clinical Endocrinology and Metabolism. 100 (5): E783-8. doi:10.1210/jc.2014-4405. PMID 25695890.
  6. ^ Larger E, Wewer Albrechtsen NJ, Hansen LH, Gelling RW, Capeau J, Deacon CF, Madsen OD, Yakushiji F, De Meyts P, Holst JJ, Nishimura E (2016). "Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation". Endocrinology, Diabetes & Metabolism Case Reports. 2016: 0081. doi:10.1530/EDM-16-0081. PMC 5118975. PMID 27933176.
  7. ^ Gild ML, Tsang V, Samra J, Clifton-Bligh RJ, Tacon L, Gill AJ (September 2018). "Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome): A New Association". The Journal of Clinical Endocrinology and Metabolism. 103 (9): 3119–3123. doi:10.1210/jc.2018-01074. PMID 30032256.
  8. ^ Li H, Zhao L, Singh R, Ham JN, Fadoju DO, Bean LJ, Zhang Y, Xu Y, Xu HE, Gambello MJ (December 2018). "GCGR is identified by newborn screening of elevated arginine". Molecular Genetics and Metabolism Reports. 17: 46–52. doi:10.1016/j.ymgmr.2018.09.006. PMC 6171159. PMID 30294546.
  9. ^ Amano S, Suenaga S, Hamamoto K, Yada S, Tsuyama T, Shinoda S, Tanaka Y, Takemoto Y, Harada E, Tanabe K, Asahara S, Hoshii K, Takami T (March 2023). "A case of multiple glucagonomas with no clinical manifestations of excess glucagon despite hyperglucagonemia". DEN Open. 3 (1): e230. doi:10.1002/deo2.230. PMC 10043567. PMID 36998346.
  10. ^ Deng W, He M, Wang W, Xue H (August 2023). "Gastrointestinal: Pancreatic NETs with GCGR heterozygous mutation: Mahvash disease". J Gastroenterol Hepatol. 38 (8): 1243. doi:10.1111/jgh.16104. PMID 36698259.
  11. ^ a b c d Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri VN, Miller J, Maley W, Shah AP, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler DS (November 2023). "Liver transplantation in a woman with Mahvash disease". New England Journal of Medicine. 389 (21): 1972–8. doi:10.1056/NEJMoa2303226. PMID 37991855.
  12. ^ a b Yu R (March 2014). "Pancreatic α-cell hyperplasia: facts and myths". The Journal of Clinical Endocrinology and Metabolism. 99 (3): 748–56. doi:10.1210/jc.2013-2952. PMID 24285676.
  13. ^ Solloway MJ, Madjidi A, Gu C, Eastham-Anderson J, Clarke HJ, Kljavin N, et al. (July 2015). "Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass". Cell Reports. 12 (3): 495–510. doi:10.1016/j.celrep.2015.06.034. PMID 26166562.
  14. ^ Yu R, Dhall D, Nissen NN, Zhou C, Ren SG (2011). "Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice". PLOS ONE. 6 (8): e23397. Bibcode:2011PLoSO...623397Y. doi:10.1371/journal.pone.0023397. PMC 3154424. PMID 21853126.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mahvash_disease&oldid=1253742184"